Brief: Immatics And Bristol Myers Squibb Enter Into Global Exclusive License For Immatics’ TCR Bispecific Program Ima401

Immatics

14/12/2021 11:59

Dec 14 (Reuters) - 
    * IMMATICS AND BRISTOL MYERS SQUIBB ENTER INTO GLOBAL
EXCLUSIVE
LICENSE FOR IMMATICS’ TCR BISPECIFIC PROGRAM IMA401
    * IMMATICS NV - ‍​COS TO COLLABORATE ON DEVELOPMENT WITH CO
RETAINING CO-PROMOTION OPTION IN U.S.
    * IMMATICS NV - ‍​BRISTOL MYERS SQUIBB SECURES GLOBAL
EXCLUSIVE
LICENSE TO CO’S TCR BISPECIFIC PROGRAM IMA401
    * IMMATICS - ‍​TO GET UPFRONT PAYMENT OF $150 MILLION,
ADDITIONAL
MILESTONE PAYMENTS OF UPTO $770 MILLION PLUS TIERED DOUBLE-DIGIT
ROYALTIES ON NET PRODUCT SALES
    * IMMATICS - ‍​TERMS OF CURRENT AGREEMENT REGARDING
IMMATICS’ TCER
IMA401 PROGRAM EXCLUDE ANY MAGEA4/8 TARGETS FOR CELL THERAPY


 ((Reuters.Briefs@thomsonreuters.com;))